A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

Trial Profile

A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results assessing overall survival and progression free survival presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 24 Feb 2017 According to a Celgene Corporation media release,the European Commission approved REVLIMID as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top